Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AFQ056 with L-dopa · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| AFQ056 100 mg (Bid) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Active | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AFQ056 with L-dopa | DRUG | hard gelatin capsule to be taken bid for six weeks |
| Placebo | DRUG | hard gelatin capsule to be taken bid for six weeks |
| AFQ056 | DRUG | - |
Inclusion Criteria: * Outpatients with Parkinson's Disease (PD), treated with L-dopa, experiencing OFF time and dyskinesias for at least three months Exclusion Criteria: * Surgical treatment for PD * Cancer within the past 5 years (other than localized skin cancer and prostate cancer that has bee...
AFQ056 is an investigational small molecule being studied for multiple conditions, including L-dopa induced dyskinesias in Parkinson's disease, hepatic impairment, cocaine use disorder, and Fragile X syndrome. It has been evaluated in clinical trials for these indications, though it remains in development and is not approved.
AFQ056 is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. Novartis has sponsored multiple clinical trials of AFQ056 across various indications and phases of development.
AFQ056 has been studied in Phase 1 and Phase 2 clinical trials. The most advanced trials are Phase 2 studies for Parkinson's disease with L-dopa induced dyskinesias and cocaine use disorder. All four completed trials are finished, and the drug remains investigational.
AFQ056 has completed four clinical trials. NCT00986414 and NCT01173731 are Phase 2 studies in Parkinson's disease with L-dopa induced dyskinesias. NCT01456663 is a Phase 1 pharmacokinetic study in hepatic impairment. NCT03242928 is a Phase 2 study in cocaine use disorder.
AFQ056 is the primary identifier for this investigational drug in clinical trial registries. No alternative names have been reported in the available data. Researchers and investors should refer to it as AFQ056 when searching for information about this compound.